Karnchanasorn Rudruidee, Ou Horng-Yih, Lin James, Chuang Lee-Ming, Chiu Ken C
Division of Endocrinology, Metabolism and Genetics, Department of Internal Medicine, University of Kansas Medical Center, Kansas, KS, USA.
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng-Kung University Medical College and Hospital, Tainan, Taiwan.
Curr Diab Rep. 2016 Oct;16(10):101. doi: 10.1007/s11892-016-0790-y.
Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.
病毒性肝炎被认为在2型糖尿病的发展中起作用。因此，通过接种疫苗预防病毒性肝炎有可能减轻2型糖尿病的负担。我们已经表明，成功接种乙肝疫苗可将糖尿病风险降低33%。虽然糖尿病可以通过行为改变和药物来预防，但这些都需要个人做出重大承诺并付出成本。相比之下，通过接种乙肝疫苗预防糖尿病所需的个人投入很少，成本也相对较低。在这篇综述中，我们讨论甲型、乙型和丙型肝炎病毒及其与糖尿病的相互作用；探讨潜在的潜在机制以及肝炎疫苗接种降低糖尿病的潜力；并估计这种干预措施将节省的医疗费用。鉴于在乙型肝炎流行的发展中地区预计糖尿病患病率会上升，探索这种干预措施非常及时。
